Myovant Sciences Ltd (MYOV)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

SUITE 1, 3RD FLOOR LONDON, UNITED KINGDOM SW1Y 4LB

Myovant Sciences Ltd. operates as a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing innovative therapies for women's health diseases and other endocrine-related disorders. Myovant Sciences develops relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids and endometriosis-associated pain.

Data based on most recent fiscal year report
Market Cap1.255 Billion Shares Outstanding89.62 Million Avg Volume1.065 Million
1-Yr BETA vs S&P TR Current Ratio2.32 Quick Ratio2.32
View SEC Filings from MYOV instead.

View recent insider trading info

Funds Holding MYOV (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding MYOV BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

2.1 Million total shares from 16 transactions

Open Market Sells (S)

785 total shares from 2 transactions

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

KARBE FRANK PRINCIPAL FIN'L & ACCOUNTING

  • Officer
163,470 2020-04-03 4

SEELY LYNN PRINCIPAL EXECUTIVE OFFICER

  • Officer
  • Director
1,889,992 2020-04-03 1

LANG MATTHEW GENERAL COUNSEL & CORP. SECY.

  • Officer
145,865 2020-04-03 3

ARJONA FERREIRA JUAN CAMILO CHIEF MEDICAL OFFICER

  • Officer
145,115 2020-04-03 2

VIKING GLOBAL INVESTORS LP

VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP

VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC

VIKING GLOBAL OPPORTUNITIES GP LLC

HALVORSEN OLE ANDREAS

OTT DAVID C.

SHABET ROSE SHARON

  • 10% Owner
3,718,284 2020-04-03 2

SABLICH KIM CHIEF COMMERCIAL OFFICER

  • Officer
146,710 2020-04-03 5

SUMITOMO CHEMICAL CO., LTD.

DAINIPPON SUMITOMO PHARMA CO LTD

SUMITOVANT BIOPHARMA LTD.

  • 10% Owner
47,068,604 2020-04-03 7

DEVEYDT WAYNE S EXEC CHAIRMAN OF THE BOARD

  • Officer
  • Director
284,075 2020-03-27 0

GULFO ADELE M.

  • Director
0 2020-03-18 2

GUINAN MARK EXECUTIVE VICE PRESIDENT & CFO

  • Officer
73,579 2020-03-10 1

ROIVANT SCIENCES LTD.

  • 10% Owner
18,577,380 2020-02-24 6

SEBELIUS KATHLEEN

0 2020-02-20 2

POTTER MYRTLE S

  • Director
12,480 2020-01-10 1

MACHADO PATRICK

  • Director
0 2020-01-01 2

NOMURA HIROSHI

  • Director
0 2019-12-27 1

TORTI FRANK

  • Director
0 2019-12-18 1

CURRAN TERRIE PRES., GLBL INFLAM. AND IMMUN.

0 2019-11-20 1

MANCHESTER KEITH S

  • Director
0 2019-08-17 0

QVT ASSOCIATES GP LLC

QVT FUND V LP

  • Director
  • 10% Owner
  • SEE REMARKSSEE REMARKS
0 2019-07-10 2

LO ANDREW

  • FORMER 10% OWNER
0 2019-07-10 2

SVF INVESTMENTS (UK) LTD

SOFTBANK VISION FUND L.P.

SVF GP (JERSEY) LTD

SVF HOLDINGS (UK) LLP

  • FORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNER
0 2019-07-10 2

DEXXON HOLDINGS LTD.

DEXCEL PHARMA TECHNOLOGIES LTD.

OREN DAN

  • SEE REMARKSSEE REMARKSSEE REMARKS
0 2019-07-10 2

VIKING GLOBAL PERFORMANCE LLC

VIKING GLOBAL EQUITIES LP

VIKING GLOBAL EQUITIES II LP

VGE III PORTFOLIO LTD.

VIKING GLOBAL EQUITIES MASTER LTD.

VIKING LONG FUND GP LLC

VIKING LONG FUND MASTER LTD.

HALVORSEN OLE ANDREAS

OTT DAVID C.

SHABET ROSE SHARON

  • FORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNER
0 2019-07-10 2

VIKING GLOBAL EQUITIES MASTER LTD.

  • 10% Owner
22,703,669 2019-01-01 0

VIKING GLOBAL PERFORMANCE LLC

VIKING GLOBAL EQUITIES LP

VIKING GLOBAL EQUITIES II LP

VGE III PORTFOLIO LTD.

VIKING LONG FUND GP LLC

VIKING LONG FUND MASTER LTD.

  • 10% Owner
22,703,669 2018-10-01 2

ALTMEYER MARK

  • Director
0 2018-08-31 0

RAMASWAMY VIVEK

  • Director
0 2018-06-19 0

TAKEDA PHARMACEUTICALS INTERNATIONAL AG

TAKEDA PHARMACEUTICAL CO LTD

TAKEDA A/S

TAKEDA EUROPE HOLDINGS B.V.

TAKEDA PHARMA A/S

  • 10% Owner
7,420,625 2018-03-19 0

MILLENNIUM PHARMACEUTICALS INC

TAKEDA PHARMACEUTICALS U.S.A., INC.

  • 10% Owner
7,420,625 2018-03-19 0

DEXCEL PHARMA TECHNOLOGIES LTD.

  • 10% Owner
16,013,540 2017-09-06 0

SHABET ROSE SHARON

  • 10% Owner
75,000,000 2017-07-01 0

TAKEDA PHARMACEUTICALS INTERNATIONAL AG

  • 10% Owner
7,420,625 2017-04-17 0

ROMEO MARIANNE L. HEAD,GLOBAL TRANS. & RISK MGMT

  • Officer
0 2016-10-26 0

DEXXON HOLDINGS LTD.

OREN DAN

  • 10% Owner
37,231,342 2016-10-26 0

VIKING GLOBAL INVESTORS LP

VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP

VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC

VIKING GLOBAL OPPORTUNITIES GP LLC

HALVORSEN OLE ANDREAS

OTT DAVID C.

SUNDHEIM DANIEL S.

  • 10% Owner
37,231,342 2016-10-26 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

SUMITOMO CHEMICAL CO., LTD. - > 10% Owner see footnote

DAINIPPON SUMITOMO PHARMA CO LTD - > 10% Owner see footnote

SUMITOVANT BIOPHARMA LTD. - > 10% Owner see footnote

2020-04-06 P 70,000 $8.44 a 47,068,604 47,068,604.00 indirect

SABLICH KIM - Officer CHIEF COMMERCIAL OFFICER

2020-04-03 A 134,464 a 134,464 146,710.00 direct

SEELY LYNN - Director - Officer PRINCIPAL EXECUTIVE OFFICER

2020-04-03 A 197,659 a 1,043,824 1,889,992.00 direct

KARBE FRANK - Officer PRINCIPAL FIN'L & ACCOUNTING

2020-04-03 A 183,991 a 183,991 163,470.00 direct

SUMITOMO CHEMICAL CO., LTD. - > 10% Owner see footnote

DAINIPPON SUMITOMO PHARMA CO LTD - > 10% Owner see footnote

SUMITOVANT BIOPHARMA LTD. - > 10% Owner see footnote

2020-04-03 P 70,000 $7.93 a 46,998,604 47,068,604.00 indirect

LANG MATTHEW - Officer GENERAL COUNSEL & CORP. SECY.

2020-04-03 A 170,396 a 170,396 145,865.00 direct

SABLICH KIM - Officer CHIEF COMMERCIAL OFFICER

2020-04-03 A 87,805 a 146,710 146,710.00 direct

ARJONA FERREIRA JUAN CAMILO - Officer CHIEF MEDICAL OFFICER

2020-04-03 A 134,464 a 134,464 145,115.00 direct

KARBE FRANK - Officer PRINCIPAL FIN'L & ACCOUNTING

2020-04-03 A 120,146 a 163,470 163,470.00 direct

LANG MATTHEW - Officer GENERAL COUNSEL & CORP. SECY.

2020-04-03 A 111,268 a 145,865 145,865.00 direct

SEELY LYNN - Director - Officer PRINCIPAL EXECUTIVE OFFICER

2020-04-03 A 302,693 a 302,693 1,889,992.00 direct

ARJONA FERREIRA JUAN CAMILO - Officer CHIEF MEDICAL OFFICER

2020-04-03 A 87,805 a 145,115 145,115.00 direct

SUMITOMO CHEMICAL CO., LTD. - > 10% Owner see footnote

DAINIPPON SUMITOMO PHARMA CO LTD - > 10% Owner see footnote

SUMITOVANT BIOPHARMA LTD. - > 10% Owner see footnote

2020-04-02 P 70,000 $7.73 a 46,928,604 46,928,604.00 indirect

SUMITOMO CHEMICAL CO., LTD. - > 10% Owner see footnote

DAINIPPON SUMITOMO PHARMA CO LTD - > 10% Owner see footnote

SUMITOVANT BIOPHARMA LTD. - > 10% Owner see footnote

2020-04-01 P 70,000 $7.46 a 46,858,604 46,928,604.00 indirect

SUMITOMO CHEMICAL CO., LTD. - > 10% Owner see footnote

DAINIPPON SUMITOMO PHARMA CO LTD - > 10% Owner see footnote

SUMITOVANT BIOPHARMA LTD. - > 10% Owner see footnote

2020-03-31 P 70,000 $7.97 a 46,788,604 46,788,604.00 indirect

SUMITOMO CHEMICAL CO., LTD. - > 10% Owner see footnote

DAINIPPON SUMITOMO PHARMA CO LTD - > 10% Owner see footnote

SUMITOVANT BIOPHARMA LTD. - > 10% Owner see footnote

2020-03-30 P 70,000 $7.65 a 46,718,604 46,788,604.00 indirect

SUMITOMO CHEMICAL CO., LTD. - > 10% Owner see footnote

DAINIPPON SUMITOMO PHARMA CO LTD - > 10% Owner see footnote

SUMITOVANT BIOPHARMA LTD. - > 10% Owner see footnote

2020-03-27 P 70,000 $7.98 a 46,648,604 46,648,604.00 indirect

SUMITOMO CHEMICAL CO., LTD. - > 10% Owner see footnote

DAINIPPON SUMITOMO PHARMA CO LTD - > 10% Owner see footnote

SUMITOVANT BIOPHARMA LTD. - > 10% Owner see footnote

2020-03-26 P 70,000 $7.94 a 46,578,604 46,648,604.00 indirect

SUMITOMO CHEMICAL CO., LTD. - > 10% Owner see footnote

DAINIPPON SUMITOMO PHARMA CO LTD - > 10% Owner see footnote

SUMITOVANT BIOPHARMA LTD. - > 10% Owner see footnote

2020-03-25 P 108,100 $7.60 a 46,508,604 46,508,604.00 indirect

SUMITOMO CHEMICAL CO., LTD. - > 10% Owner see footnote

DAINIPPON SUMITOMO PHARMA CO LTD - > 10% Owner see footnote

SUMITOVANT BIOPHARMA LTD. - > 10% Owner see footnote

2020-03-24 P 211,200 $7.67 a 46,400,504 46,508,604.00 indirect

SUMITOMO CHEMICAL CO., LTD. - > 10% Owner see footnote

DAINIPPON SUMITOMO PHARMA CO LTD - > 10% Owner see footnote

SUMITOVANT BIOPHARMA LTD. - > 10% Owner see footnote

2020-03-23 P 211,200 $7.68 a 46,189,304 46,189,304.00 indirect

SUMITOMO CHEMICAL CO., LTD. - > 10% Owner see footnote

DAINIPPON SUMITOMO PHARMA CO LTD - > 10% Owner see footnote

SUMITOVANT BIOPHARMA LTD. - > 10% Owner see footnote

2020-03-20 P 193,900 $7.60 a 45,978,104 46,189,304.00 indirect

SUMITOMO CHEMICAL CO., LTD. - > 10% Owner see footnote

DAINIPPON SUMITOMO PHARMA CO LTD - > 10% Owner see footnote

SUMITOVANT BIOPHARMA LTD. - > 10% Owner see footnote

2020-03-19 P 193,900 $7.68 a 45,784,204 45,784,204.00 indirect

SUMITOMO CHEMICAL CO., LTD. - > 10% Owner see footnote

DAINIPPON SUMITOMO PHARMA CO LTD - > 10% Owner see footnote

SUMITOVANT BIOPHARMA LTD. - > 10% Owner see footnote

2020-03-18 P 193,900 $7.40 a 45,590,304 45,784,204.00 indirect

SABLICH KIM - Officer CHIEF COMMERCIAL OFFICER

2020-03-18 S 15 $6.93 d 58,905 58,905.00 direct

SABLICH KIM - Officer CHIEF COMMERCIAL OFFICER

2020-03-18 S 770 $7.38 d 58,920 58,905.00 direct

SUMITOMO CHEMICAL CO., LTD. - > 10% Owner see footnote

DAINIPPON SUMITOMO PHARMA CO LTD - > 10% Owner see footnote

SUMITOVANT BIOPHARMA LTD. - > 10% Owner see footnote

2020-03-17 P 193,900 $7.40 a 45,396,404 45,396,404.00 indirect

SUMITOMO CHEMICAL CO., LTD. - > 10% Owner see footnote

DAINIPPON SUMITOMO PHARMA CO LTD - > 10% Owner see footnote

SUMITOVANT BIOPHARMA LTD. - > 10% Owner see footnote

2020-03-16 P 193,900 $7.25 a 45,202,504 45,396,404.00 indirect

GULFO ADELE M. - Director

2020-02-24 A 45,000 a 45,000 0.00 direct

Elevate your investments